Scott Z Fields

US Patent:

7976852, Jul 12, 2011

Filed:

Apr 26, 2006

Appl. No.:

11/411332

Inventors:

Daniel P. Rossignol - Ridgefield Park NJ, US
Sally T. Ishizaka - Weston MA, US
Lynn D. Hawkins - Concord MA, US
Scott Z. Fields - Towaco NJ, US

Assignee:

Eisai R&D Management Co., Ltd. - Tokyo

International Classification:

A61K 31/395

US Classification:

4242771, 4241781, 5142633, 514183, 514269

Abstract:

The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.

US Patent:

8603482, Dec 10, 2013

Filed:

Jun 13, 2011

Appl. No.:

13/158786

Inventors:

Daniel P. Rossignol - Ridgefield Park NJ, US
Sally T. Ishizaka - Weston MA, US
Lynn D. Hawkins - Andover MA, US
Scott Fields - Towaco NJ, US

Assignee:

Eisai R&D Management Co., Ltd. - Bunkyo-Ku, Tokyo

International Classification:

A61K 39/395
A61P 35/00

US Classification:

4241741, 4242781

Abstract:

The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.

US Patent:

20020069154, Jun 6, 2002

Filed:

May 8, 2001

Appl. No.:

09/851533

Inventors:

Scott Fields - Blue Bell PA, US

International Classification:

G06F017/60

US Classification:

705/037000

Abstract:

An apparatus for managing communications between a patent attorney and prospective client comprising: a control unit for receiving a client request generated by a prospective client, relating to a desire for legal services including a fee request; means for assisting a client in formulating a request for proposal to be distributed to a patent attorney throughout the system; means for distributing the request for proposal to said attorneys; and means for receiving bids from attorneys who receive the request for proposal.

US Patent:

20040186127, Sep 23, 2004

Filed:

Jan 7, 2004

Appl. No.:

10/753261

Inventors:

Jane Daun - Dracut MA, US
Scott Fields - Towaco NJ, US
Seiichi Kobayashi - Belmont MA, US

Assignee:

Eisai Co., Ltd. - Tokyo

International Classification:

C07D471/02
A61K031/4745

US Classification:

514/303000, 546/119000

Abstract:

The present invention provides methods of using compounds having formula (I): wherein R, R, Rand n are as described generally and in classes and subclasses herein, in the treatment of reperfusion injuries, osteoporosis and/or bone metastasis.

US Patent:

20060270709, Nov 30, 2006

Filed:

Apr 4, 2006

Appl. No.:

11/396555

Inventors:

Julian Gray - Inzlingen, DE
Yoshiharu Yamanishi - Tsukuba-shi, JP
Nobuyuki Mori - Tsukuba-shi, JP
Scott Fields - Towaco NJ, US

Assignee:

Eisai Co. Ltd. - Bunkyo-ku

International Classification:

A61K 31/445
A61K 31/444

US Classification:

514332000, 514319000

Abstract:

The invention provides methods for treating and/or preventing cognitive impairments, dementia, or neurodegenerative diseases and disorders (e.g., Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis) in patients by administering therapeutically effective amounts of an AMPA receptor antagonist (e.g., 1,2-dihydropyridine compounds) and therapeutically effective amounts of nootropics (e.g., cholinesterase inhibitors) to patients. The invention also provides combinations, commercial packages, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists (e.g., 1,2-dihydropyridine compounds) and therapeutically effective amounts nootropics (e.g., cholinesterase inhibitors). The 1,2-dihydropyridine compound may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The cholinesterase inhibitor may be, for example, donepezil.

US Patent:

20070015789, Jan 18, 2007

Filed:

Jan 11, 2006

Appl. No.:

11/332711

Inventors:

Jay Barth - Teaneck NJ, US
Kathleen Lomax - Teaneck NJ, US
Scott Fields - Teaneck NJ, US
Mindell Seidlin - Teaneck NJ, US

International Classification:

A61K 31/46

US Classification:

514304000

Abstract:

The invention provides safe and effective methods for treating and/or preventing gastrointestinal disorders, psychiatric disorders, learning disabilities, Tourette's syndrome, obesity, epilepsy, post-menopausal syndrome, pre-menstrual syndrome, asthma, laryngitis and/or migraines by administering to a patient in need thereof at least one aminobenzoic acid compound. The aminobenzoic acid compound can optionally be administered in combination with other medications that are useful for the disease being treated.

US Patent:

20070292418, Dec 20, 2007

Filed:

Nov 28, 2006

Appl. No.:

11/605557

Inventors:

Scott Fields - Ridgefield Park NJ, US
Lynn Hawkins - Andover MA, US
Sally Ishizaka - Andover MA, US
Daniel Rossignol - Ridgefield Park NJ, US

International Classification:

A61K 39/395
A61P 43/00

US Classification:

424133100, 424130100, 424142100, 424158100

Abstract:

The invention relates to immunotherapeutic compounds, compositions that include such compounds, and methods of using the compounds, for example, to treat an individual having, at risk for, or previously treated for a cancer.

US Patent:

20080070944, Mar 20, 2008

Filed:

Sep 20, 2007

Appl. No.:

11/902338

Inventors:

Jay Barth - Teaneck NJ, US
Kathleen Lomax - Teaneck NJ, US
Scott Fields - Teaneck NJ, US
Mindell Seidlin - Teaneck NJ, US

Assignee:

EISAI Co., Ltd. - Tokyo

International Classification:

A61K 31/439
A61P 3/04

US Classification:

514305000

Abstract:

The invention provides safe and effective methods for treating and/or preventing gastrointestinal disorders, psychiatric disorders, learning disabilities, Tourette's syndrome, obesity, epilepsy, post-menopausal syndrome, pre-menstrual syndrome, asthma, laryngitis and/or migraines by administering to a patient in need thereof at least one aminobenzoic acid compound. The aminobenzoic acid compound can optionally be administered in combination with other medications that are useful for the disease being treated.